A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.

@article{Alvarez2014API,
  title={A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.},
  author={Ronald D. Alvarez and Michael W. Sill and Susan A. Davidson and Carolyn Y. Muller and David P. Bender and Robert L. Debernardo and Kian Behbakht and Warner K Huh},
  journal={Gynecologic oncology},
  year={2014},
  volume={133 3},
  pages={433-8}
}
OBJECTIVE The purpose of this phase II trial was to evaluate the toxicity and antitumor activity of EGEN-001 in platinum resistant recurrent ovarian cancer. METHODS Eligible patients had weekly IP infusion of EGEN-001 at a dose of 24mg/m(2). Toxicity and antitumor activity were evaluated using CTCAE and RESIST criteria, respectively. Co-primary endpoints were tumor response and survival without progression (PFS) for at least 6months. Survival without progression before going onto a subsequent… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

In Vivo Delivery Systems for Therapeutic Genome Editing

International journal of molecular sciences • 2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Immunotherapy in ovarian cancer.

Human vaccines & immunotherapeutics • 2012
View 1 Excerpt

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…